Inhibikase Therapeutics reported its Q3 2025 results, focusing on advancing its lead candidate IKT-001 for Pulmonary Arterial Hypertension (PAH). The company is preparing to initiate a Phase 2b clinical trial in Q4 2025, while R&D and SG&A expenses have significantly increased due to ongoing development and a prior acquisition.
Appointed Timothy Pigot as Chief Commercial and Strategy Officer, a veteran biopharma executive.
neutralCash, cash equivalents, and marketable securities totaled $77.3 million as of September 30, 2025.
neutralInterest income increased significantly to $838,093 for Q3 2025 from $49,410 in Q3 2024.
positiveNet loss widened to $11.9 million ($0.13/share) in Q3 2025 from $5.8 million ($0.65/share) in Q3 2024.
negativeResearch and development expenses more than doubled to $7.6 million in Q3 2025 from $4.2 million in Q3 2024.
attentionSelling, general and administrative expenses increased substantially to $5.6 million in Q3 2025 from $1.6 million in Q3 2024.
attentionCash reserves decreased to $77.3 million from $97.5 million at the beginning of the year.
attentionMargin metrics will be available once backend extracts data from insights_json
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
Continued to position the Company to advance IKT-001 toward a late-stage clinical trial in PAH.
Expect to initiate Phase 2b clinical study of IKT-001 in PAH during the fourth quarter of 2025.
Proposed Phase 2b IMPROVE-PAH trial is a multi-center, randomized, double-blind, placebo-controlled study of approximately 150 PAH participants.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.